Regulation & Policy

MarketReports.com | Pharmaceuticals & Healthcare |  Regulation & Policy

Post Marketing Clinical Research - REMS, the Latest Reformation due to Post Marketing Surveillance to Enhance Patient Compliance Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 17-Sep-2011 Format: PDF Pages: 82 Publisher: GBI Research More...

Drug Recalls and Warning Letters - Increasing Numbers Caused by Manufacturing Errors and Regulatory Non-compliance Issues Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 07-Nov-2011 Format: PDF Pages: 128 Publisher: GBI Research More...

Healthcare Reform in the US - Impact on Pricing and Reimbursement Price Single User $500.00 Site License $1,000.00 Global Site License $1,500.00 Publication Date: 30-Apr-2011 Format: PDF Pages: 5 Publisher: GlobalData More...

Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 24-May-2011 Format: PDF Pages: 88 Publisher: GBI Research More...

Impact of Counterfeits on Pharmaceutical Industry - Counterfeiting Poses Threats to Patient Safety and Revenues of Pharmaceutical Companies Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 10-Jun-2011 Format: PDF Pages: 95 Publisher: GBI Research More...

Impact of US Healthcare Reforms - the Extension of Care to 32 Million Uninsured Citizens from 2014 and Implications for the Pharmaceutical Industry Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 10-Jun-2011 Format: PDF Pages: 87 Publisher: GBI Research More...

Pharmaceutical Key Trends 2011 – Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify Price: $3,800.00 (€2,891.26) ($4,560.00 (€3,469.51) Including VAT at 20%) Publication Date: 25-Mar-2011 Please click here for more information or to purchase this report at our partner store Analysis of healthcare expenditure, reforms, pricing and reimbursement and drug regulation across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.

FDA Changes Suggested in 510(k) Process - Impact and Opportunities Price Single User $500.00 Site License $1,000.00 Global Site License $1,500.00 Publication Date: 27-Apr-2011 Format: PDF Pages: 11 Publisher: GlobalData More...

Hit by the Infamous Patent Cliff, Big Pharma Strategize Counter Measures for the Future Price Single User $500.00 Site License $1,000.00 Global Site License $1,500.00 Publication Date: 27-Apr-2011 Format: PDF Pages: 5 Publisher: GlobalData More...

Reforms to the Pharmaceutical Benefits Scheme in Australia Price: $500.00 (€380.43) ($600.00 (€456.51) Including VAT at 20%) Publication Date: 04-Feb-2011 Please click here for more information or to purchase this report at our partner store An overview of the role of the Pharmaceutical Benefits Scheme in Australia, and a brief examination of the impacts of recent reforms to the reimbursement scheme on various stakeholder groups, including innovator and generic medicines manufacturers.

Patent Strategies - Effective Strategies for Extension of Product Lifecycles and Combating Aggressive Generics Markets Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: Dec-2010 Format: PDF Pages: 71 Publisher: GBI Research More...

Intellectual Property Protection and Regulatory Regimes in Emerging Markets Price: $3,835.00 (€2,917.89) ($4,602.00 (€3,501.46) Including VAT at 20%) Publication Date: 14-Dec-2010 Please click here for more information or to purchase this report at our partner store Pharmaceutical sales in emerging markets have been expanding rapidly in recent years, and are likely to account for a significant share of global pharma industry growth over the next 5 years. However, concerns remain about the lack of IP protection.

Obama's Healthcare Reform Bill and its Impact on the U.S. Healthcare Market Price Single User $4,650.00 Multi User $5,650.00 Corporate Licence $7,150.00 Enterprise Site Licence $9,000.00 Publication Date: 16-Aug-2010 Format: pdf Pages: 145 Publisher: MarketsandMarkets Table of Contents According to World Health Organization, the U.S. healthcare system ranks 37th among the healthcare systems of 200 countries. The U.S. healthcare spending is considered as one of the highest in the world as healthcare expenditure in the country accounts to 17.5% of its GDP (2009) as compared to an average of 8% to 9% in the Organization for Economic Co-operation and Development (OECD) countries. However, the rising healthcare costs and increasing health premium rates, along with high number of uninsured people (about 47 million, i.e., approximately 16% of the total population) are among the significant factors contributing to the need for healthcare reforms in the U.S. Healthcare reforms in the country are looked upon as an initiative toward provision of affordable health coverage for all Americans, and improvement in quality and efficiency of healthcare. More...

Healthcare Regulatory Update: The United Arab Emirates - The widening gap in healthcare access between Abu Dhabi and Dubai Price: $3,800.00 (€2,891.26) ($4,560.00 (€3,469.51) Including VAT at 20%) Publication Date: 07-Jan-2010 Please click here for more information or to purchase this report at our partner store An update of the latest regulatory healthcare reforms in Abu Dhabi and Dubai, with analysis of the impact of these changes on key stakeholders in the healthcare sector, plus reviews the latest commercial trends adopted in the industry.

MarketReports.com | Pharmaceuticals & Healthcare |  Regulation & Policy